Hologic, a leader in breast health, in vitro diagnostics, gynecological surgery, and bone health, announced the completion of its go private acquisition led jointly by private equity giants Blackstone and TPG. At the same time, a key management transition was finalized: the company formally appointed José (Joe) E. Almeida, a veteran leader in the medical technology industry, as Chief Executive Officer, effective immediately upon announcement.

This management change took place efficiently and in quick succession. Just one day earlier, on April 6, Hologic disclosed that Steve MacMillan, its long serving CEO, would retire upon completion of the privatization transaction. In a single day, this century old healthcare giant completed both its capital restructuring and leadership transition, officially entering a new phase of development.
The high profile privatization deal was first agreed in October 2025, when Hologic reached a definitive acquisition agreement with funds managed by Blackstone and TPG. The transaction valued Hologic at up to $79 per share, corresponding to a total enterprise value of as much as $18.3 billion.
On February 5, 2026, Hologic shareholders approved the landmark transaction. Following completion, Hologic’s common stock ceased trading on the NASDAQ stock exchange and will be formally delisted, transforming the public company into a private enterprise backed by private equity funds.
Under the terms of the deal, Hologic shareholders will receive a fixed cash consideration of $76 per share, plus a non tradable contingent value right (CVR). Through this instrument, shareholders may be entitled to receive up to an additional $3 per share in two installments of up to $1.50 each. These additional payments are directly tied to the achievement of specific global revenue targets for Hologic’s core breast health business in fiscal years 2026 and 2027.
Notably, this multi billion dollar transaction also attracted participation from leading global sovereign wealth funds. A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC, Singapore’s sovereign wealth fund, both participated as significant minority investors, providing strong capital support for Hologic’s future growth.
Taking the helm at Hologic, Joe Almeida is a highly experienced executive with a proven track record in the medical technology industry.

José (Joe) E. Almeida

Prior to joining Hologic, Almeida headed Baxter International, a renowned global healthcare company, for nearly a decade. From 2016 to early 2025, he served as Chairman, President and Chief Executive Officer, leading the company through a profound strategic transformation. During his tenure, he drove the implementation of a new operating model and accelerated technological innovation, creating long-term and stable value growth for the enterprise. In February 2025, Almeida announced his retirement from Baxter International but remained as a consultant until October of that year to ensure a smooth leadership transition.
Before joining Baxter, Almeida boasted an illustrious career. He served as Chairman, President and Chief Executive Officer of Covidien plc until the healthcare giant was acquired by Medtronic in 2015. Earlier in his career, he held senior management positions at Tyco Healthcare, and also served as an executive at Wilson Greatbatch Technologies, Acufex Microsurgical, and Codman & Shurtleff, a core subsidiary of Johnson & Johnson. With decades of deep roots in the medical industry, he has accumulated irreplaceable practical experience and industry insights spanning cutting-edge R&D to global operations.
Expressing his excitement and aspirations for leading Hologic, Almeida stated: "Hologic is an exceptional company with a profound history of innovation and an unrivaled leadership position in global women's health. I am thrilled to join at this pivotal moment. With the support of Blackstone and TPG, we will embrace a new mission, invest greater resources in innovation, help the company scale new heights, and fulfill our core vision of enabling healthier lives for people worldwide."
As the lead sponsors of the privatization, Blackstone and TPG also hold high expectations for the new leader.
Ram Jagannath, Senior Managing Director and Global Head of Healthcare at Blackstone, remarked that Hologic has long been a benchmark for advancing global women's health, delivering outstanding results with a suite of life-changing medical technologies. Partnering with a top medical tech leader like Almeida and Hologic's exceptional management team will undoubtedly propel the company into a new era of growth and innovation.
Alex Abate, Partner and Co-Head of Healthcare at TPG Capital, also noted that investing in healthcare innovation has always been TPG's core strategy. The firm has long admired Hologic's leadership in women's health and believes that under Almeida's guidance, Hologic will uphold standards of clinical excellence and create tangible value for patients worldwide.
Headquartered in Marlborough, Massachusetts, Hologic has always focused on early detection and precision treatment, dedicated to safeguarding women's health globally. It has established an unassailable industry barrier in core sectors including breast health, diagnostics, and gynecological surgery.
Now, with the completion of the $18.3 billion privatization transaction, Hologic—delisted from the NASDAQ—has shed the short-term performance constraints of a public company. Under the stewardship of veteran industry leader Almeida and backed by the long-term support of top-tier capital, this women's health giant is poised to move forward boldly, accelerating innovation and global expansion.
A brand-new era for Hologic has officially begun.